Generic drug
Isoniazid price, strengths & recalls
Pharmacies pay $99.67 for 30 tablets of Isoniazid 300 mg tablet this week, and from $51.97 to $99.67 across its 2 priced strengths and forms. 13 manufacturers make it. It has 3 recalls on record, none ongoing. Its official label last changed on November 17, 2025.
Generic- Fair cash price
- $125.12
- Strengths
- 2
- Makers
- 13
- Updated
- Nov 11
Isoniazid price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 100 mg/mL injection | Not priced this week | |||
| 10 mg/mL oral solution | Not priced this week | |||
| 100 mg tablet | $1.73 | $51.97 / 30 tablets | ||
| 300 mg tablet | $3.32 | $99.67 / 30 tablets | ||
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Isoniazid
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
Isoniazid Tablets, USP
WARNING
Severe and sometimes fatal hepatitis associated with isoniazid therapy has been reported and may occur or may develop even after many months of treatment. The risk of developing hepatitis is age related. Approximate case rates by age are: less than 1 per 1,000 for persons under 20 years of age, 3 per 1,000 for persons in the 20 to 34 year age group, 12 per 1,000 for persons in the 35 to 49 year age group, 23 per 1,000 for persons in the 50 to 64 year age group and 8 per 1,000 for persons over 65 years of age. The risk of hepatitis is increased with daily consumption of alcohol. Precise data to provide a fatality rate for isoniazid-related hepatitis is not available; however, in a U.S. Public Health Service Surveillance Study of 13,838 persons taking isoniazid, there were 8 deaths among 174 cases of hepatitis.
Therefore, patients given isoniazid should be carefully monitored and interviewed at monthly intervals. For persons 35 and older, in addition to monthly symptom reviews, hepatic enzymes (specifically, AST and ALT [formerly SGOT and SGPT, respectively]) should be measured prior to starting isoniazid therapy and periodically throughout treatment. Isoniazid-associated hepatitis usually occurs during the first three months of treatment. Usually, enzyme levels return to normal despite continuance of drug, but in some cases progressive liver dysfunction occurs. Other factors associated with an increased risk of hepatitis include daily use of alcohol, chronic liver disease and injection drug use. A recent report suggests an increased risk of fatal hepatitis associated with isoniazid among women, particularly black and Hispanic women. The risk may also be increased during the post partum period. More careful monitoring should be considered in these groups, possibly including more frequent laboratory monitoring. If abnormalities of liver function exceed three to five times the upper limit of normal, discontinuation of isoniazid should be strongly considered. Liver function tests are not a substitute for a clinical evaluation at monthly intervals or for the prompt assessment of signs or symptoms of adverse reactions occurring between regularly scheduled evaluations. Patients should be instructed to immediately report signs or symptoms consistent with liver damage or other adverse effects. These include any of the following: unexplained anorexia, nausea, vomiting, dark urine, icterus, rash, persistent paresthesias of the hands and feet, persistent fatigue, weakness or fever of greater than 3 days duration and/or abdominal tenderness, especially right upper quadrant discomfort. If these symptoms appear or if signs suggestive of hepatic damage are detected, isoniazid should be discontinued promptly, since continued use of the drug in these cases has been reported to cause a more severe form of liver damage.
Patients with tuberculosis who have hepatitis attributed to isoniazid should be given appropriate treatment with alternative drugs. If isoniazid must be reinstituted, it should be reinstituted only after symptoms and laboratory abnormalities have cleared. The drug should be restarted in very small and gradually increasing doses and should be withdrawn immediately if there is any indication of recurrent liver involvement.
Preventive treatment should be deferred in persons with acute hepatic diseases.
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Generic makers
- 7 approved generic applications on the market
Isoniazid questions
How much does isoniazid cost without insurance?
Pharmacies pay about $99.67 for 30 tablets of isoniazid 300 mg tablet ($3.32 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $125.12. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is isoniazid in shortage?
No shortage is reported for isoniazid right now. We check the national shortage list every day.
Has isoniazid been recalled?
3 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the isoniazid label last change?
The official label was last updated on November 17, 2025 (version 1). See what changed.
Talk about isoniazid
No comments yet. Questions, tips, what worked for you - start the conversation.